486 related articles for article (PubMed ID: 17440047)
1. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.
Carnevale RP; Proietti CJ; Salatino M; Urtreger A; Peluffo G; Edwards DP; Boonyaratanakornkit V; Charreau EH; Bal de Kier Joffé E; Schillaci R; Elizalde PV
Mol Endocrinol; 2007 Jun; 21(6):1335-58. PubMed ID: 17440047
[TBL] [Abstract][Full Text] [Related]
2. Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases.
Skildum A; Faivre E; Lange CA
Mol Endocrinol; 2005 Feb; 19(2):327-39. PubMed ID: 15486045
[TBL] [Abstract][Full Text] [Related]
3. Progesterone signaling in breast and endometrium.
Ballaré C; Vallejo G; Vicent GP; Saragüeta P; Beato M
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):2-10. PubMed ID: 17070033
[TBL] [Abstract][Full Text] [Related]
4. Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators.
Faivre E; Skildum A; Pierson-Mullany L; Lange CA
Steroids; 2005; 70(5-7):418-26. PubMed ID: 15862825
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV
Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765
[TBL] [Abstract][Full Text] [Related]
6. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells.
Proietti C; Salatino M; Rosemblit C; Carnevale R; Pecci A; Kornblihtt AR; Molinolo AA; Frahm I; Charreau EH; Schillaci R; Elizalde PV
Mol Cell Biol; 2005 Jun; 25(12):4826-40. PubMed ID: 15923602
[TBL] [Abstract][Full Text] [Related]
7. Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.
Ibrahim YH; Byron SA; Cui X; Lee AV; Yee D
Mol Cancer Res; 2008 Sep; 6(9):1491-8. PubMed ID: 18819936
[TBL] [Abstract][Full Text] [Related]
8. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
9. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.
Izzo F; Mercogliano F; Venturutti L; Tkach M; Inurrigarro G; Schillaci R; Cerchietti L; Elizalde PV; Proietti CJ
Breast Cancer Res; 2014 Dec; 16(6):491. PubMed ID: 25479686
[TBL] [Abstract][Full Text] [Related]
10. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
11. Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth.
Daniel AR; Qiu M; Faivre EJ; Ostrander JH; Skildum A; Lange CA
Steroids; 2007 Feb; 72(2):188-201. PubMed ID: 17173941
[TBL] [Abstract][Full Text] [Related]
12. Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor.
McGowan EM; Russell AJ; Boonyaratanakornkit V; Saunders DN; Lehrbach GM; Sergio CM; Musgrove EA; Edwards DP; Sutherland RL
Cancer Res; 2007 Sep; 67(18):8942-51. PubMed ID: 17875737
[TBL] [Abstract][Full Text] [Related]
13. Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors.
Faivre EJ; Daniel AR; Hillard CJ; Lange CA
Mol Endocrinol; 2008 Apr; 22(4):823-37. PubMed ID: 18202149
[TBL] [Abstract][Full Text] [Related]
14. Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.
Puricelli L; Proietti CJ; Labriola L; Salatino M; Balañá ME; Aguirre Ghiso J; Lupu R; Pignataro OP; Charreau EH; Bal de Kier Joffé E; Elizalde PV
Int J Cancer; 2002 Aug; 100(6):642-53. PubMed ID: 12209601
[TBL] [Abstract][Full Text] [Related]
15. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
Labriola L; Salatino M; Proietti CJ; Pecci A; Coso OA; Kornblihtt AR; Charreau EH; Elizalde PV
Mol Cell Biol; 2003 Feb; 23(3):1095-111. PubMed ID: 12529413
[TBL] [Abstract][Full Text] [Related]
16. Activation of mitogen- and stress-activated kinase 1 is required for proliferation of breast cancer cells in response to estrogens or progestins.
Reyes D; Ballaré C; Castellano G; Soronellas D; Bagó JR; Blanco J; Beato M
Oncogene; 2014 Mar; 33(12):1570-80. PubMed ID: 23604116
[TBL] [Abstract][Full Text] [Related]
17. Chromatin remodeling and control of cell proliferation by progestins via cross talk of progesterone receptor with the estrogen receptors and kinase signaling pathways.
Vicent GP; Ballaré C; Zaurin R; Saragüeta P; Beato M
Ann N Y Acad Sci; 2006 Nov; 1089():59-72. PubMed ID: 17261755
[TBL] [Abstract][Full Text] [Related]
18. Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells.
Wu J; Brandt S; Hyder SM
Mol Endocrinol; 2005 Feb; 19(2):312-26. PubMed ID: 15528272
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
[TBL] [Abstract][Full Text] [Related]
20. Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form a or B of the progesterone receptor and then treatment with progestins.
Sumida T; Itahana Y; Hamakawa H; Desprez PY
Cancer Res; 2004 Nov; 64(21):7886-92. PubMed ID: 15520195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
